기업 프로필 · Healthcare

Abbott Laboratories

ABT · 미국
거래소
미국
국가 / 지역
USA
상장일
1978년 1월 13일
직원 수
122,000
웹사이트
www.abbott.com
현재가
$104.49
실시간 · 2026년 7월 27일
베일리 성장 점수
47/100
다소 약함
내재가치 · 3단계 구간 현재가 $104.49 실시간 · 적정 내재가치 구간 내

종합 밸류에이션 구간 · 보수적 $70–$85 / 적정 $90–$105 / 낙관적 $115–$135. $104.49 기준, 적정 내재가치 구간 내.

보고서 발행 시 $88.38(2026년 5월 21일)

시가총액US$1795.11억
매출 (TTM)US$465.85억
EBITDAUS$118.67억
순이익률11.65%
ROE12.33%
PER (TTM)32.61
선행 PER18.28
PEG2.03
EPSUS$3.16
배당수익률2.46%
52주 범위US$81.39 – US$134.38
애널리스트 목표주가US$119.13
애널리스트 평가4.3 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

연혁

Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois. Formerly known as Abbott Alkaloidal Company, it changed its name to Abbott Laboratories in 1915, and its IPO is dated January 13, 1978. By 2026 the company had achieved 54 consecutive years of dividend increases and 409 consecutive quarterly dividends. In the first quarter of 2026 (March 2026) Abbott completed its acquisition of Exact Sciences, entering oncology diagnostics, raising nearly USD 19.86B in new long-term debt to finance the deal.

업계 내 위치

Abbott is a Healthcare-sector company in Medical Devices, operating in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In 2025 net sales were USD 44.328B (segment revenue: Medical Devices USD 21.387B, Diagnostics USD 8.937B, Nutrition USD 8.451B, Established Pharma USD 5.536B), with R&D of USD 2.942B (6.6%). It employs 122,000 people and operates across 160+ countries, holding an A+/Aa3 investment-grade rating. Key products include FreeStyle Libre (over 7 million users), Ensure, Glucerna, Similac and Alinity; competitors named are DexCom, Medtronic, Boston Scientific, BD, Danaher and Roche.

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.